<div class="indication">
    <h1>Indication</h1>
    <div class="group">
        <h2>Approved indication(s)</h2>
        <ul>
            <li>Adults with locally advanced or metastatic urothelial cancer (mUC), in combination with pembrolizumab.</li>
            <li>Adults with locally advanced or mUC who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and platinum-containing chemotherapy, or are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.</li>
        </ul>
    </div>

    <div class="group">
        <h2>Ongoing clinical trial indication(s)</h2>
        <p> Metastatic breast cancer (Phase 3)</p>
    </div>

    <div class="group">
        <h2>Unapproved indication(s)</h2>
        <p>Genitourinary Cancer</p>
    </div>
</div>
